Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “outperform” rating restated by equities research analysts at William Blair in a research report issued to clients and investors on Tuesday.
Other equities research analysts have also issued reports about the company. Morgan Stanley lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $78.00 to $58.00 in a research report on Tuesday. Jefferies Group restated a “hold” rating and set a $66.00 price target on shares of Bristol-Myers Squibb in a research report on Friday. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Thursday, February 8th. BMO Capital Markets decreased their price objective on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 6th. Finally, Leerink Swann increased their price objective on Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $65.34.
NYSE BMY opened at $54.20 on Tuesday. The company has a market cap of $95,750.99, a P/E ratio of 18.01, a price-to-earnings-growth ratio of 1.52 and a beta of 0.96. Bristol-Myers Squibb has a one year low of $51.56 and a one year high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. Bristol-Myers Squibb’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 EPS. analysts forecast that Bristol-Myers Squibb will post 3.22 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of BMY. Renaissance Technologies LLC boosted its position in shares of Bristol-Myers Squibb by 108.5% in the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after purchasing an additional 7,020,200 shares during the last quarter. BlackRock Inc. boosted its position in shares of Bristol-Myers Squibb by 5.0% in the 4th quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after purchasing an additional 4,945,515 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after purchasing an additional 3,735,453 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Bristol-Myers Squibb by 2,990.5% in the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after purchasing an additional 3,516,536 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Bristol-Myers Squibb by 42,071.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after purchasing an additional 3,323,649 shares during the last quarter. Institutional investors and hedge funds own 71.51% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/17/bristol-myers-squibb-bmy-receives-outperform-rating-from-william-blair.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.